Comparative structural modeling and docking studies of uricase: Possible implication in enzyme supplementation therapy for hyperuricemic disorders

Uricase (EC 1.7.3.3, UC) catalyzes the oxidation of uric acid (UA) to more soluble allantoin thereby lowering plasma UA levels. In humans, when concentration of UA exceeds >7mg/dl, it leads to hyperuricemia, gout, nephrolithiasis and urolithiasis. A new remedy to cure such metabolic diseases is the enzyme supplementation therapy by UC but with high degree of antigenic independence. Therefore screening of new uricase sources to expand its usefulness and reduced antigenecity is needed. Present study employed cheminformatics approach to construct models of reported UC from different sources viz. Bacillus megaterium, Streptomyces bingchenggensis BCW-1, Paenibacillus sp, Solibacter usitatus Ellin6076, Truepera radiovictrix DSM 17093 and Ktedonobacter racemifer DSM 4496 in order to study their structure-function relationship for enzyme mass production and modification for improved characteristics. BioMed CAChe version 6.1 was further used to study enzyme-substrate interactions of models with uric acid using docking approach. Results indicated that models for UC of Streptomyces bingchenggensis BCW-1 accounted for better regio-specificity towards UA, supporting the interested metabolism and thus may further be implicated in enzyme supplementation therapy for hyperuricemic associated disorders.

[1]  Z. Xiang,et al.  Advances in homology protein structure modeling. , 2006, Current protein & peptide science.

[2]  M S Baig,et al.  Homology modeling and docking studies of Comamonas testosteroni B-356 biphenyl-2,3-dioxygenase involved in degradation of polychlorinated biphenyls. , 2010, International journal of biological macromolecules.

[3]  G. Marzluf,et al.  Purification and characterization of uricase, a nitrogen-regulated enzyme, from Neurospora crassa. , 1980, Archives of biochemistry and biophysics.

[4]  K. Cheng,et al.  Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. , 2009, Biochemical pharmacology.

[5]  F. Melo,et al.  Assessing protein structures with a non-local atomic interaction energy. , 1998, Journal of molecular biology.

[6]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[7]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[8]  B. Vogt,et al.  Urate oxidase (rasburicase) for treatment of severe tophaceous gout. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Bo Zhang,et al.  Genome Sequence of the Milbemycin-Producing Bacterium Streptomycesbingchenggensis , 2010, Journal of bacteriology.

[10]  Qing-Chuan Zheng,et al.  A comparative analysis of binding sites between mouse CYP2C38 and CYP2C39 based on homology modeling, molecular dynamics simulation and docking studies. , 2009, Biochimica et biophysica acta.

[11]  M. Sippl.  Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.

[12]  T G Conley,et al.  Purification of uricase from mammalian tissue. , 1979, Preparative biochemistry.

[13]  Xiuping He,et al.  Uricase production by a recombinant Hansenula polymorpha strain harboring Candida utilis uricase gene , 2008, Applied Microbiology and Biotechnology.

[14]  Eva Liebau,et al.  Structural modeling and simulation studies of Brugia malayi glutathione-S-transferase with compounds exhibiting antifilarial activity: implications in drug targeting and designing. , 2010, Journal of molecular graphics & modelling.

[15]  Xiaohang Ma,et al.  Purification and characterization of a thermostable uricase from Microbacterium sp. strain ZZJ4-1 , 2008 .

[16]  R. Eman,et al.  Optimum conditions for uricase enzyme production by Gliomastix gueg , 2009 .

[17]  M. Hershfield,et al.  Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout , 2009 .

[18]  H. Edelsbrunner,et al.  Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design , 1998, Protein science : a publication of the Protein Society.

[19]  P. Caliceti,et al.  Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). , 2000, Farmaco.

[20]  Mike A. Clark,et al.  Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase , 2004, Current rheumatology reports.

[21]  K Henrick,et al.  Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions , 2022 .

[22]  Bernard Henrissat,et al.  Three Genomes from the Phylum Acidobacteria Provide Insight into the Lifestyles of These Microorganisms in Soils , 2009, Applied and Environmental Microbiology.

[23]  Ragini G. Bodade,et al.  Microbial and xanthine dehydrogenase inhibitory activity of some flavones , 2008, Journal of enzyme inhibition and medicinal chemistry.

[25]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[26]  Bhaskar S. Dawane,et al.  Synthesis and biological activity of pyrazolo[3,4-d]thiazolo[3,2-a]pyrimidin-4-one derivatives: in silico approach , 2010, Journal of enzyme inhibition and medicinal chemistry.

[27]  Weihua Li,et al.  Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. , 2009, Journal of molecular graphics & modelling.

[28]  Dieter Jahn,et al.  Genome Sequences of the Biotechnologically Important Bacillus megaterium Strains QM B1551 and DSM319 , 2011, Journal of bacteriology.

[29]  Satoru Shimizu,et al.  Structures of Arthrobacter globiformis urate oxidase-ligand complexes. , 2008, Acta crystallographica. Section D, Biological crystallography.

[30]  R G Bodade,et al.  Homology modeling and docking study of xanthine oxidase of Arthrobacter sp. XL26. , 2010, International journal of biological macromolecules.

[31]  Torsten Schwede,et al.  The SWISS-MODEL Repository and associated resources , 2008, Nucleic Acids Res..

[32]  Akbar Nayeem,et al.  A comparative study of available software for high‐accuracy homology modeling: From sequence alignments to structural models , 2006, Protein science : a publication of the Protein Society.

[33]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[34]  Massoud Amanlou,et al.  Molecular modeling of Helicobacter pylori arginase and the inhibitor coordination interactions. , 2010, Journal of molecular graphics & modelling.

[35]  Mohammad Ali Faramarzi,et al.  Mucor hiemalis: a new source for uricase production , 2006 .

[36]  C N Khobragade,et al.  Comparative structural modeling and docking studies of oxalate oxidase: Possible implication in enzyme supplementation therapy for urolithiasis. , 2011, International journal of biological macromolecules.

[37]  T. Mikuls,et al.  Understanding treatments for gout. , 2005, The American journal of managed care.

[38]  Xiaolan Yang,et al.  A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia , 2010, Archives of pharmacal research.

[39]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[40]  C. Pui,et al.  Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial , 2001, Leukemia.

[41]  D. Eisenberg,et al.  VERIFY3D: assessment of protein models with three-dimensional profiles. , 1997, Methods in enzymology.

[42]  P. Spencer,et al.  Biochemical and biopharmaceutical properties of PEGylated uricase. , 2010, International journal of pharmaceutics.